YoonHwa An/LinkedIn
Sep 14, 2026, 20:53
YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
YoonHwa An, Founder and Principal Strategist, External Strategic Red Team at Biopharma Business Intelligence Unit, shared a post on LinkedIn:
“Rusfertide in Polycythemia Vera: From Clinical Benefit to Strategic Value
Rusfertide’s FDA approval creates a new option for controlling erythrocytosis in polycythemia vera. For clinicians, payers and investors, the next question is how that benefit translates into treatment decisions and sustainable value.
BBIU’s latest Strategic Report examines the connections:
- Clinical evidence: What VERIFY’s response endpoint establishes—and the remaining uncertainty around thrombosis, disease progression and long-term outcomes.
- Health economics: Why avoided phlebotomies alone are unlikely to offset acquisition costs at the reported list price.
- Market access: How coverage, treatment burden and emerging competitors could influence adoption.
- Corporate governance: How Protagonist’s agreement with Takeda shifts commercial exposure, and what investors should examine in royalty economics, executive incentives and capital allocation.
The report connects the clinical findings to the decisions facing biopharma executives, investors and healthcare stakeholders.
Available in BBIU’s Strategic Reports. Access currently requires a free account.”
Stay updated with Hemostasis Today.
-
Oct 30, 2026, 17:43Santagata Davide: Can Targeting Inflammation Help Prevent Thrombosis?
-
Oct 30, 2026, 17:38Patrick Ellsworth: Supporting Patients and Families Through Bleeding Disorders Awareness and Community Initiatives
-
Oct 30, 2026, 17:33Ed Shovelin: Comparative Hemostatic Performance of CRP-A and Equine Fibrillar Collagen
-
Oct 30, 2026, 16:52Tosin Ola: A New Era in Sickle Cell Disease Treatment and the Question of Access
-
Oct 30, 2026, 16:48Cedric Hermans: The Next Generation of FVIIIa-Mimetic Antibodies in Haemophilia A
-
Oct 30, 2026, 16:44Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management